Calliditas Therapeutics AB announced that the Chinese regulatory authority National Medical Products Administration has accepted Everest Medicines' New Drug Application for Nefecon. The acceptance brings Nefecon, approved and marketed in the U.S. under the name TARPEYO® and in the E.U. as Kinpeygo®, an important step closer to potentially becoming the first-ever approved therapeutic option indicated for primary IgAN treatment in China. In December 2020, the NMPA recommended Breakthrough Therapy Designation ("BTD") for Nefecon for the treatment of IgAN.

Chronic kidney disease is one of the most serious public health problems in China, where IgAN is estimated by Everest to affect around five million people.